• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment

bySze Wah Samuel ChanandHarsh Shah
April 12, 2021
in Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma.

2. Lenvatinib plus pembrolizumab demonstrated longer progression-free survival compared to sunitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The standard treatment of advanced renal cell carcinoma (RCC) has been antagonism of vascular endothelial growth factor (VEGF) with tyrosine kinase inhibitors such as sunitinib. Lenvatinib, an antiangiogenic agent, and pembrolizumab, an anti-programmed cell death 1 monoclonal antibody, have been explored in previous studies as monotherapies for RCC. As such, this study reported the efficacy and safety of lenvatinib plus pembrolizumab treatment compared to sunitinib in patients with advanced RCC. The study determined pembrolizumab plus lenvatinib treated patients had superior progression-free survival and overall survival compared to sunitinib. The most common adverse event was diarrhea, which was greater in the combination therapy group. There was more drug discontinuation in the lenvatinib and pembrolizumab group compared to the lenvatinib and everolimus group or the sunitinib group. One limitation is that patients and investigators were aware of the treatment assignments. Overall, this trial demonstrated that lenvatinib and immune-checkpoint inhibition with pembrolizumab showed superior survival compared to sunitinib alone.

Click here to read the study in the NEJM

Relevant Reading: Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

In-Depth [randomized controlled trial]: This was a multicenter, randomized, open-label trial of 1,069 patients from 200 sites in 20 countries. Patients 18 years of age or older with advanced renal carcinoma, and no prior systemic therapy were included in the study. Patients were excluded from the study if there was not adequate blood pressures control or organ function. Patients were randomized in a 1:1:1 ratio into lenvatinib and pembrolizumab, lenvatinib and everolimus, or sunitinib, respectively. Everolimus and lenvatinib treatment (median, 14.7 months) had significantly longer progression-free survival compared to sunitinib (median, 9.2 months) (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.53 to 0.80; P < 0.001). However, the overall survival between both groups was not significant (HR, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Pembrolizumab and lenvatinib was superior in both progression-free survival (treatment median, 23.9 months; control median, 9.2 months; HR, 0.39; 95% CI, 0.32 to 0.49; P < 0.001) and overall survival (HR, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) when compared to sunitinib. Grade 3 or higher adverse events was observed in 82.4% of the lenvatinib plus pembrolizumab group, 83.1% of the lenvatinib plus everolimus group, and 71.8% of the patients who received sunitinib. In general, this trial demonstrated the use of an immune checkpoint inhibitor is an important treatment component for advanced RCC in combination with standard VEGF inhibition.

RELATED REPORTS

Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: lenvatinibPembrolizumabrenal-cell carcinoma
Previous Post

Direct oral anticoagulants more effective in patients with valvular atrial fibrillation

Next Post

Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes

RelatedReports

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

April 18, 2022
Increased frailty associated with childhood cancer survivorship
Oncology

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

March 27, 2022
#VisualAbstract: Fulvestrant plus cyclin-dependent kinase 4/6 inhibitors improves survival in HR⁺, HER2- metastatic breast cancer
StudyGraphics

#VisualAbstract: Time-of-infusion with immunotherapy may impact survival outcomes for patients with advanced melanoma

February 16, 2022
Cervical cancer screening practices less cost-effective than suggested guidelines
Obstetrics

Pembrolizumab improves survival outcomes in cervical cancer patients

February 15, 2022
Next Post
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Clinicopathological heterogeneity in triple-negative breast cancers associated with variable prognosis and therapeutic outcomes

Time-limited trials may decrease the length of stay of critically ill patients in the intensive care unit

#VisualAbstract: Protection from SARS-CoV-2 re-infection may be diminished among elderly individuals

#VisualAbstract: Tislelizumab plus chemotherapy improves outcomes for advanced squamous non small cell lung cancer over chemotherapy alone

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.